You just read:

AcelRx Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study (IAP312) for Zalviso™ in 1Q 2016

News provided by

AcelRx Pharmaceuticals, Inc.

Jan 08, 2016, 07:00 ET